Pyridostigmine for the Treatment of Constipation in Parkinson Disease

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Vermont Medical Center

About this trial

Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Be able to provide signed informed consent

Stated ability and willingness to comply with all study procedures

Able to take oral medications

Disqualifiers

Diagnosis of atypical parkinsonism

Diagnosis of drug-induced parkinsonism

Diagnosis of vascular parkinsonism

Known allergy to pyridostigmine bromide or other study drug components

Trial design

Treatments tested in this trial

  • Pyridostigmine Bromide

Treatment groups

16 Participants
are divided into 1 treatment group